Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label lurasidone extension in schizophrenia
2016-000061-23Phase 3Completed
- Sponsor
- Sunovion
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sunovion. Primary endpoint: Safety Endpoint. Started Jun 2016; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-000061-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000061-23.